Blood distribution of bortezomib and its kinetics in multiple myeloma patients

被引：11

作者：

Osawa, Takashi ^{[1
]}

Naito, Takafumi ^{[1
]}

Kaneko, Takanori ^{[1
,2
]}

Mino, Yasuaki ^{[1
]}

Ohnishi, Kazunori ^{[3
]}

Yamada, Hiroshi ^{[2
]}

Kawakami, Junichi ^{[1
]}

机构：

[1] Hamamatsu Univ Sch Med, Dept Hosp Pharm, Hamamatsu, Shizuoka 4313192, Japan

[2] Univ Shizuoka, Grad Sch Pharmaceut Sci, Dept Drug Evaluat & Informat, Shizuoka 4228526, Japan

[3] Hamamatsu Univ Sch Med, Ctr Oncol, Hamamatsu, Shizuoka 4313192, Japan

来源：

CLINICAL BIOCHEMISTRY | 2014年 / 47卷 / 15期

关键词：

Bortezomib; Blood distribution; Multiple myeloma; Pharmacokinetics; Therapeutic drug monitoring; PROTEASOME INHIBITOR BORTEZOMIB; DRUG-DRUG INTERACTION; ADVANCED SOLID TUMORS; EXTENDED FOLLOW-UP; PROTEIN-BINDING; ERYTHROCYTES; TRIAL; PHARMACOKINETICS; METABOLISM;

D O I：

10.1016/j.clinbiochem.2014.06.077

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Objectives: Pharmacokinetic disposition of bortezomib in the blood has not been fully characterized in humans. This study aimed to evaluate the blood distribution of bortezomib and its kinetics in multiple myeloma patients. Design and method: Eighteen multiple myeloma patients receiving bortezomib-dexamethasone combination therapy were enrolled. Blood specimens were drawn just before bortezomib administration on days 1 and 8 in the second and third cycles and after discontinuation. The relationships between bortezomib concentration and blood components were evaluated. Results: Bortezomib concentration in the blood on day 1 was higher than that on day 8 in the second cycle. No difference was observed in bortezomib blood concentrations between day 8 in the second and third cycles. The bortezomib concentration in the blood and blood cells was 3- and 7-fold higher than that in plasma. Bortezomib concentration in the blood was correlated with the red blood cell count. The half-life of bortezomib in the blood was 23 days. Conclusion: Bortezomib was taken up into red blood cells to only a limited extent and eliminated in parallel to the red blood cells' lifespan. The turnover of red blood cells can affect the pharmacokinetic disposition of bortezomib in multiple myeloma patients. (C) 2014 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

引用

页码：54 / 59

页数：6

共 50 条

[31] Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide [J].

Castro, T. B. M. ;

Hallack Neto, A. E. ;

Atalla, A. ;

Ribeiro, L. C. .

BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2016, 49 (06) :e5128

[32] Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma [J].

Manochakian, Rami ;

Miller, Kena C. ;

Chanan-Khan, Asher A. .

ONCOLOGIST, 2007, 12 (08) :978-990

[33] Efficiency of bortezomib, melfalane, and prednisolone combination in patients with multiple myeloma [J].

Luchinin, A. S. ;

Zagoskina, T. P. .

GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2009, 54 (04) :9-13

[34] Bortezomib-induced neurogenic bladder in patients with multiple myeloma [J].

Kazuho Shimura ;

Chihiro Shimazaki ;

Kyoko Taniguchi ;

Tohru Inaba ;

Shigeo Horiike ;

Masafumi Taniwaki .

Annals of Hematology, 2009, 88 :383-384

[35] Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma [J].

Rupa-Matysek, Joanna ;

Gil, Lidia ;

Wojtasinska, Ewelina ;

Nowicki, Adam ;

Dytfeld, Dominik ;

Kazmierczak, Maciej ;

Komarnicki, Mieczyslaw .

THROMBOSIS RESEARCH, 2014, 134 (02) :404-411

[36] Optimizing therapy in bortezomib-exposed patients with multiple myeloma [J].

Migkou, Magdalini ;

Gavriatopoulou, Maria ;

Terpos, Evangelos ;

Dimopoulos, Meletios Athanasios .

EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (06) :463-469

[37] Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib [J].

Berenson, Ariana ;

Vardanyan, Suzie ;

David, Michael ;

Wang, James ;

Harutyunyan, Nika Manik ;

Gottlieb, Jillian ;

Halleluyan, Ran ;

Spektor, Tanya M. ;

Udd, Kyle A. ;

Eshaghian, Shahrooz ;

Nassir, Youram ;

Eades, Benjamin ;

Swift, Regina ;

Berenson, James R. .

ANNALS OF HEMATOLOGY, 2017, 96 (03) :449-459

[38] Safety and Efficacy of Targeted-Dose Busulfan and Bortezomib as a Conditioning Regimen for Patients with Relapsed Multiple Myeloma Undergoing a Second Autologous Blood Progenitor Cell Transplantation [J].

Freytes, Cesar O. ;

Toro, Juan J. ;

Yeh, Rosa F. ;

Stadtmauer, Edward A. ;

Ratanatharathorn, Voravit ;

Akpek, Goerguen ;

Sahovic, Entezam ;

Tricot, Guido J. ;

Shaughnessy, Paul J. ;

White, Darrell J. ;

Rodriguez, Tulio E. ;

Solomon, Scott R. ;

Yu, Louie H. ;

Zhao, Cathy ;

Patil, Shiva ;

Armstrong, Elizabeth ;

Smith, Angela ;

Elekes, Agnes ;

Kato, Kazunobu ;

Reece, Donna E. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (12) :1949-1957

[39] Update on the optimal use of bortezomib in the treatment of multiple myeloma [J].

Mohan, Meera ;

Matin, Aasiya ;

Davies, Faith E. .

CANCER MANAGEMENT AND RESEARCH, 2017, 9 :51-63

[40] Linking the activity of bortezomib in multiple myeloma and autoimmune diseases [J].

Skrott, Zdenek ;

Cvek, Boris .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 92 (02) :61-70

← 1 2 3 4 5 →